158 related articles for article (PubMed ID: 2677240)
1. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
Schiwy W; Heath WR; Delini-Stula A
J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
[TBL] [Abstract][Full Text] [Related]
2. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
[TBL] [Abstract][Full Text] [Related]
3. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
4. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Fritze J; Becker T; Ziegler V; Laux G; Riederer P
Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
[TBL] [Abstract][Full Text] [Related]
5. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
6. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
Volz HP; Faltus F; Magyar I; Möller HJ
J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
[TBL] [Abstract][Full Text] [Related]
7. Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients.
Bremner JD; Abrahams LM; Crupie JE; McCawley A; Proctor RC; Sathananthan GL
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):56-9. PubMed ID: 6370976
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
10. Reversible monoamine oxidase-A inhibitors in panic disorder.
Bakish D; Saxena BM; Bowen R; D'Souza J
Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
[TBL] [Abstract][Full Text] [Related]
12. [Brofaromine--a selective, reversible and short-acting MAO-A inhibitor].
Möller HJ; Wendt G
Psychiatr Prax; 1989 Aug; 16 Suppl 1():32-6. PubMed ID: 2685854
[TBL] [Abstract][Full Text] [Related]
13. Nomifensine in the treatment of depressed geriatric patients.
Goldstein SE; Birnbom F; Laliberte R
J Clin Psychiatry; 1982 Jul; 43(7):287-9. PubMed ID: 7045090
[TBL] [Abstract][Full Text] [Related]
14. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
15. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
J Affect Disord; 1994 Oct; 32(2):105-14. PubMed ID: 7829762
[TBL] [Abstract][Full Text] [Related]
16. Nomifensine vs. imipramine in depressed inpatients.
Fann WE; Lyle FA; Higginbotham W
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):60-2. PubMed ID: 6370978
[TBL] [Abstract][Full Text] [Related]
17. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
Suominen J; Tamminen T; Elosuo R; Manniche PM
Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Celada P; Pérez J; Alvarez E; Artigas F
J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
[TBL] [Abstract][Full Text] [Related]
20. A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients.
Merideth CH; Feighner JP; Hendrickson G
J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):73-7. PubMed ID: 6370981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
